nach oben

Erschienen in:

31.07.2017 | Research Paper

Next generation sequencing of progressive colorectal liver metastases after portal vein embolization

verfasst von: Eve Simoneau, Jarred Chicoine, Sarita Negi, Ayat Salman, Anthoula Lazaris, Mazen Hassanain, Nicole Beauchemin, Stephanie Petrillo, David Valenti, Ramila Amre, Peter Metrakos

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Portal vein embolization (PVE) can be required to stimulate liver regeneration before hepatectomy for colorectal liver metastasis (CRCLM), however PVE may also trigger CRCLM progression in patients initially exhibiting chemotherapy response. Using RNA-seq, we aimed to determine the molecular networks involved in metastatic progression in this context. A prospective study including all CRCLM patients undergoing PVE prior to hepatectomy was conducted. Paired biopsies of metastatic lesions were obtained prior to and after PVE and total RNA was isolated and used to prepare Illumina rRNA-depleted TruSeq stranded cDNA libraries for HiSeq 100 bp paired-end sequencing. Patients were classified with progression of disease (PD_PVE) or stable disease (SD_PVE) post-PVE using 3D-CT tumor volumetric analysis. Results: Twenty patients were included, 13 (65.0%) in the PD_PVE group (median 58.0% (18.6–234.3) increase in tumor volume) and 7 (35.0%) in the SD_PVE group exhibiting continuous chemotherapy response (median −14.3% (−40.8 to −2.8) decrease in tumor volume) (p < 0.0001). Our results showed that progressive CRCLM after PVE undergo gene expression changes that indicate activation of core cancer pathways (IL-17 (p = 5.94 × 10⁻⁰³), PI3K (p = 8.71 × 10⁻⁰³), IL6 and IGF-1 signaling pathways), consistent with changes driven by cytokines and growth factors. Differential expression analysis in a paired model of progression (EdgeR, DeSeq) identified significantly dysregulated genes in the PD_PVE group (FOS, FOSB, RAB20, IRS2). Conclusion: Differentially expressed genes and pathways with known links to cancer and metastasis were identified post-PVE in patients with disease progression. Highlighting these molecular changes is a crucial first step towards development of targeted therapeutic strategies that may mitigate the effects of PVE on tumor growth.

Nur mit Berechtigung zugänglich

Abdalla EK (2010) Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 102:960–967. doi:10.1002/jso.21654 CrossRefPubMed

Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Jiao LR (2008) Preoperative portal vein embolization for major liver resection. Ann Surg 247:49–57. doi:10.1097/SLA.0b013e31815f6e5b CrossRefPubMed

Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H (2004). Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240, 1052–1061 (Discussion 1061–1064)CrossRefPubMedPubMedCentral

Ak G, Metintas M, Metintas S, Yildirim H, Ozkan R, Ozden H (2010) Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. Eur J Radiol 74:130–135. doi:10.1016/j.ejrad.2009.02.002 CrossRefPubMed

Angel P, Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129–157PubMed

Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P (2003) Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE. Acta Radiol 44:98–102PubMed

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D’Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306–1315CrossRefPubMed

Dawson JC, Bruche S, Spence HJ, Braga, VMM, Machesky LM (2012) Mtss1 promotes cell-cell junction assembly and stability through the small GTPase Rac1. PLoS ONE 7:e31141. doi:10.1371/journal.pone.0031141 CrossRefPubMedPubMedCentral

De Jong KP, Lont HE, Bijma AM, Brouwers M (1995) The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies. Hepatology 22:1263–1272CrossRefPubMed

10.

Eferl R, Wagner EF (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3:859–868. doi:10.1038/nrc1209 CrossRefPubMed

11.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026 CrossRefPubMed

12.

Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P (1999) During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 86:784–788. doi:10.1046/j.1365-2168.1999.01154.x CrossRefPubMed

13.

Eveno C, Le Henaff C, Audollent R, Soyer P, Rampanou A, Nemeth J, Brouland J-P, Dupuy E, Pocard M, Bonnin P (2012) Tumor and non-tumor liver angiogenesis is traced and evaluated by hepatic arterial ultrasound in murine models. Ultrasound Med Biol 38:1195–1204. doi:10.1016/j.ultrasmedbio.2012.03.004 CrossRefPubMed

14.

Fausto N, Campbell JS, Riehle KJ (2006) Liver regeneration. Hepatology 43:S45–S53. doi:10.1002/hep.20969 CrossRefPubMed

15.

Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240, 438–47 (Discussion 447–450)CrossRefPubMedPubMedCentral

16.

Heinrich S, Jochum W, Graf R, Clavien P-A (2006) Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and liver regeneration in mice. J Hepatol 45:35–42. doi:10.1016/j.jhep.2006.02.020 CrossRefPubMed

17.

Hennigan RF, Hawker KL, Ozanne BW (1994) Fos-transformation activates genes associated with invasion. Oncogene 9:3591–3600PubMed

18.

Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the tree study. J Clin Oncol 26:3523–3529. doi:10.1200/JCO.2007.15.4138 CrossRefPubMed

19.

Hoekstra LT, van Lienden KP, Doets A., Busch ORC, Gouma DJ, van Gulik, TM (2012. Tumor progression after preoperative portal vein embolization. Ann Surg 256, 812–817 (Discussion 817–818). doi:10.1097/SLA.0b013e3182733f09 CrossRefPubMed

20.

Hu E, Mueller E, Oliviero S, Papaioannou VE, Johnson R, Spiegelman BM (1994) Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. Embo J 13:3094–3103PubMedPubMedCentral

21.

Hurwitz H., Fehrenbacher L, Novotny W., Cartwright T, Hainsworth J. Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. doi:10.1056/NEJMoa032691 CrossRefPubMed

22.

Jeon D-G, Kong C-B, Cho WH, Song WS, Cho SH, Choi SW, Lee S-Y (2014) Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma. J Surg Oncol 109:275–279. doi:10.1002/jso.23496 CrossRefPubMed

23.

Jones S, Zhang X, Parsons DW, Lin, J.C.-H., Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong S-M, Fu B, Lin M-T, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806. doi:10.1126/science.1164368 CrossRefPubMedPubMedCentral

24.

Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, Ohta K, Yamaguchi T, Matsubara T, Takahashi T, Nakajima T, Muto T, Ikari T, Yanagisawa A, Kato Y (2001) Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 34:267–272. doi:10.1053/jhep.2001.26513 CrossRefPubMed

25.

Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD (2007) Portal branch ligation induces a hepatic arterial buffer response, microvascular remodeling, normoxygenation, and cell proliferation in portal blood-deprived liver tissue. Am J Physiol Gastrointest Liver Physiol 292:G1534–G1542. doi:10.1152/ajpgi.00503.2006 CrossRefPubMed

26.

Lee Y-G, Macoska JA, Korenchuk S, Pienta KJ (2002) MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 4:291–294. doi:10.1038/sj.neo.7900231 CrossRefPubMedPubMedCentral

27.

Lim C, Cauchy F, Azoulay D, Farges O, Ronot M, Pocard M (2013) Tumour progression and liver regeneration-insights from animal models. Nat Rev Gastroenterol Hepatol. doi:10.1038/nrgastro.2013.55 PubMed

28.

Liu K, Wang G, Ding H, Chen Y, Yu G, Wang J (2010) Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer. BMC Cancer 10:428. doi:10.1186/1471-2407-10-428 CrossRefPubMedPubMedCentral

29.

Madoff DC, Abdalla EK, Vauthey J-N (2005) Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 16:779–790. doi:10.1097/01.RVI.0000159543.28222.73 CrossRefPubMed

30.

Maggiori L, Bretagnol F, Sibert A, Paradis V, Vilgrain V, Panis Y (2011) Selective portal vein ligation and embolization induce different tumoral responses in the rat liver. Surgery 149:496–503. doi:10.1016/j.surg.2010.10.012 CrossRefPubMed

31.

McGarry LC, Winnie JN, Ozanne BW (2004) Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene 23:5284–5292. doi:10.1038/sj.onc.1207687 CrossRefPubMed

32.

Michalopoulos GK (2007) Liver regeneration. J Cell Physiol 213:286–300. doi:10.1002/jcp.21172 CrossRefPubMedPubMedCentral

33.

Momiyama M, Kumamoto T, Suetsugu A, Kishimoto H, Chishima T, Tanaka K, Akiyama H, Ichikawa Y, Bouvet M, Endo I, Hoffman RM (2012) Major liver resection stimulates stromal recruitment and metastasis compared with repeated minor resection. J Surg Res 178:280–287. doi:10.1016/j.jss.2012.03.020 CrossRefPubMedPubMedCentral

34.

Mueller L, Hillert C, Möller L, Krupski-Berdien G, Rogiers X, Broering DC (2008) Major hepatectomy for colorectal metastases: is preoperative portal occlusion an oncological risk factor? Ann Surg Oncol 15:1908–1917. doi:10.1245/s10434-008-9925-y CrossRefPubMed

35.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole, ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD) (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14:1208–1215. doi:10.1016/S1470-2045(13)70447-9 CrossRefPubMed

36.

Pamecha V, Levene A, Grillo F, Woodward N, Dhillon A, Davidson BR (2009) Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer 100:617–622. doi:10.1038/sj.bjc.6604872 CrossRefPubMedPubMedCentral

37.

Picardo A, Karpoff HM, Ng B, Lee J, Brennan MF, Fong Y (1998) Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery 124:57–64CrossRefPubMed

38.

Rauchfuss F, Lambeck S, Claus RA, Ullmann J, Schulz T, Weber M, Katenkamp K, Guthke R, Bauer M, Settmacher U (2012) Sustained liver regeneration after portal vein embolization a human molecular pilot study. Dig Liver Dis 44:681–688. doi:10.1016/j.dld.2012.04.002 CrossRefPubMed

39.

Reichmann E, Schwarz H, Deiner EM, Leitner I (1992) Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell 71:1103–1116CrossRefPubMed

40.

Richter S, Vollmar B, Mücke I, Post S, Menger MD (2001) Hepatic arteriolo-portal venular shunting guarantees maintenance of nutritional microvascular supply in hepatic arterial buffer response of rat livers. J Physiol (Lond) 531:193–201CrossRef

41.

Saltz LB, Clarke S, Díaz-Rubio E (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRefPubMed

42.

Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77:1241–1246CrossRefPubMed

43.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: A Cancer J Clin 63:11–30. doi:10.3322/caac.21166

44.

Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999. doi:10.1038/sj.bjc.6603033 CrossRefPubMedPubMedCentral

45.

Simoneau E, Aljiffry M, Salman A, Abualhassan N, Cabrera T, Valenti D, El Baage A, Jamal M, Kavan P, Al-Abbad S, Chaudhury P, Hassanain M, Metrakos P (2012) Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford) 14:461–468. doi:10.1111/j.1477-2574.2012.00476.x CrossRef

46.

Taub R (2004) Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5:836–847. doi:10.1038/nrm1489 CrossRefPubMed

47.

Yokoyama Y, Wawrzyniak A, Sarmadi AM, Baveja R, Gruber HE, Clemens MG, Zhang JX (2006) Hepatic arterial flow becomes the primary supply of sinusoids following partial portal vein ligation in rats. J Gastroenterol Hepatol 21:1567–1574. doi:10.1111/j.1440-1746.2006.04460.x CrossRefPubMed

48.

Yu JS, Koujak S, Nagase S, Li C-M, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, Hibshoosh H, Tycko B, Parsons R (2008) PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27:4657–4665. doi:10.1038/onc.2008.101 CrossRefPubMedPubMedCentral

Titel: Next generation sequencing of progressive colorectal liver metastases after portal vein embolization
verfasst von: Eve Simoneau
Jarred Chicoine
Sarita Negi
Ayat Salman
Anthoula Lazaris
Mazen Hassanain
Nicole Beauchemin
Stephanie Petrillo
David Valenti
Ramila Amre
Peter Metrakos
Publikationsdatum: 31.07.2017
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 5/2017
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-017-9855-9

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Next generation sequencing of progressive colorectal liver metastases after portal vein embolization

Abstract

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

PIPAC puts pressure on peritoneal metastases from pancreatic cancer

Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases

Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)

Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?

The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review

Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie